SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2019 - 2018 - 2017 - 2016

November 2018 Scleroderma News

Statins Inhibit Cytokines in a Dose–Dependent Response in Patients with Systemic Sclerosis (SSc). Statins, particularly simvastatin, appear to have an immunosuppressive effect in reducing all cytokine secretion levels from peripheral blood mononuclear cells of SSc in a dose–dependent manner. PubMed, Inflammation, 10/04/2018. (Also see Statins and Cytokines)

A Potential Link Between Oxidative Stress and Endothelial–to–Mesenchymal Transition (EndMT) in Systemic Sclerosis (SSc). We identified studies investigating associations reactive oxygen species and EndMT highlighting a potential link between oxidative stress and EndMT in SSc. PubMed, Front Immunol, 2018 Sep 19;9:1985. (Also see Oxidative Stress)

Lung transplantation in scleroderma: recent advances and lessons. Both short–term and long–term outcomes following lung transplantation are comparable to counterparts with fibrotic lung disease or pulmonary arterial hypertension. PubMed, Curr Opin Rheumatol, 2018 Nov;30(6):562-569. (Also see Lung Transplants and Lung Transplants for Pulmonary Hypertension)

Case Report: Surgical management of raised intra–ocular tension in the hostile ocular surface – recurrent tube erosion in a patient with systemic sclerosis. In patients with systemic disease such as scleroderma, pre–operative immunosuppression helps to reduce the of erosion in difficult cases. PubMed, BMC Ophthalmol. (Also see Eye Involvement)

Anti-RNPC3 (U11/U12) antibodies in systemic sclerosis are associated with moderate to severe gastrointestinal dysmotility. After adjusting for relevant covariates and potential confounders, moderate to severe GI disease was associated with anti-RNPC3 antibodies. PubMed, Arthritis Care Res (Hoboken), 09/22/2018. (Also see Antibodies and Dysmotility)

Recent progress in systemic sclerosis–interstitial lung disease (SSc–ILD). The implications of much of this ongoing work is our ability to identify those patients at risk for progression, and to offer novel therapies that can limit the progression of inflammatory and fibrotic lung disease. PubMed, Curr Opin Rheumatol, 2018 Nov;30(6):570-575. (Also see Pulmonary Fibrosis)

Prediction of therapeutic response before and during i.v. cyclophosphamide (IVCY) pulse therapy for interstitial lung disease in systemic sclerosis (SSc–ILD): A longitudinal observational study. ILD severity/activity before treatment and variability of serum Krebs von den Lungen-6, surfactant protein D levels during treatment may be useful to predict therapeutic effects of IVCY on SSc–ILD. PubMed, J Dermatol, 10/05/2018. (Also see Pulmonary Fibrosis Treatments)

Prevalence of auto–antibodies associated to pulmonary arterial hypertension in scleroderma – A review. The available evidence points in the direction of a strong association between auto–immune mechanisms and pulmonary hypertension in the setting of scleroderma. PubMed, Autoimmun Rev, 10/11/2018. (Also see Pulmonary Hypertension and Antibodies)

Radiological images of interstitial pneumonia in mixed connective tissue disease (MCTD) compared with scleroderma (SSc) and polymyositis/dermatomyositis(PM/DM). HRCT images in MCTD patients can be classified as SSc pattern or PM/DM pattern. PubMed, Eur J Radiol, 2018 Oct;107:26-32. (Also see Correlation between Pulmonary Fibrosis and other Diseases, Mixed Connective Tissue Disease and Dermatomyositis and Polymyositis)

Mimetics of systemic sclerosis (SSc). An early differential diagnostic distinction between SSc and other sclerosing diseases is important due to SSc–associated and potentially life–threatening systemic organ involvement. PubMed, Z Rheumatol, 09/25/2018. (Also see Difficult Diagnosis)

Go to Scleroderma Medical News: October 2018
 

We have the world's best supporters! See ISN News.

 

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.
 

The most important thing in the world to know about scleroderma is sclero.org!